Emerging research suggest Retatrutide , a dual stimulator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide , may offer a significant development for obesity treatment. Initial human tests have demonstrated impressive reductions in body tissue, conceivably exceeding current obesity medications . However , further evaluation is n